二甲双胍与他汀类药物对转移性去势抵抗性前列腺癌男性患者结局的影响:COU-AA-301与COU-AA-302的二次分析
该研究为COU-AA-301和COU-AA-302两项试验的二次分析,按二甲双胍和他汀使用分层,评估其与总生存(OS)及前列腺特异性抗原应答率(PSA-RR)的关联。合并分析显示,二甲双胍与OS延长相关(合并HR 0.77,95%CI 0.62-0.95),他汀亦与OS延长相关(合并HR 0.78,95%CI 0.68-0.88),尤其在联合阿比特龙加泼尼松/泼尼松龙(AAP)时。
要点
- COU-AA-301-AAP组中,二甲双胍与PSA-RR改善相关(41.1% vs 28.6%),但未延长OS。
- COU-AA-302-AAP组中,二甲双胍与OS延长相关(adjHR 0.69,95%CI 0.48-0.98),PSA-RR改善(72.7% vs 60.0%)。
- 合并分析中,二甲双胍(合并HR 0.77,95%CI 0.62-0.95)和他汀(合并HR 0.78,95%CI 0.68-0.88)均与OS延长相关。
核心结论
- 在事后亚组分析的局限性内,二甲双胍和他汀与OS延长及PSA-RR提高相关,尤其在联合AAP时。
研究设计与样本
- COU-AA-301和COU-AA-302试验的二次分析,患者按二甲双胍和他汀使用分层。
- 采用Cox比例风险模型估计分层于合并用药的风险比(HR),并用随机效应模型合并HR;PSA-RR比较采用卡方检验。
主要发现
- COU-AA-301-AAP组中,二甲双胍与PSA-RR改善相关(41.1% vs 28.6%),但未延长OS。
- COU-AA-301-placebo-P组中,二甲双胍与OS延长或PSA-RR均无关联。
- COU-AA-302-AAP组中,二甲双胍与OS延长相关(adjHR 0.69,95%CI 0.48-0.98),PSA-RR改善(72.7% vs 60.0%)。
- COU-AA-302-P组中,二甲双胍与OS延长相关(adjHR 0.66,95%CI 0.47-0.93)。
- 合并分析中,二甲双胍治疗者OS延长(合并HR 0.77,95%CI 0.62-0.95);他汀治疗者OS亦延长(合并HR 0.78,95%CI 0.68-0.88)。
关键数值与推荐
- COU-AA-301-AAP组中,他汀与OS改善相关(adjHR 0.76,95%CI 0.62-0.93),COU-AA-301-P组中无差异。
- COU-AA-302两组中,他汀与OS均无关联。
- 合并分析中,他汀与OS延长相关(合并HR 0.78,95%CI 0.68-0.88)。
局限性
- 原文述及局限性为事后亚组分析(post-hoc sub-analyses)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. OBJECTIVE: To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. DESIGN, SETTING AND PARTICIPANT: COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. RESULTS: In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48-0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47-0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62-0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62-0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68-0.88). CONCLUSION: Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP.
引用
- Wilson BE, Armstrong AJ, de Bono J, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer. 2022. PMID: 35568679. doi:10.1016/j.ejca.2022.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。